The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
New draft guidance could see the agency getting ever stricter.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Interius, one of the most advanced players, will cost $350m.
Posters and mini-orals include another VEGF bispecific.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Summit and Nuvalent have scored prized plenary spots.
